Journal
CURRENT OPINION IN HIV AND AIDS
Volume 13, Issue 6, Pages 486-491Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/COH.0000000000000495
Keywords
drug-drug interactions; HIV; multidrug-resistant tuberculosis; treatment; tuberculosis
Categories
Funding
- Johns Hopkins University School of Medicine Clinician Scientist Career Development Award
- Gilead Foundation
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health [1K23AI135102, R21AI122922]
- National Institutes of Health Office of the Director, Fogarty International Center, Office of AIDS Research, National Cancer Center, National Heart, Blood, and Lung Institute
- NIH Office of Research for Women's Health through the Fogarty Global Health Fellows Program Consortium comprised of the University of North Carolina
- Tulane [R25TW009340]
- John Hopkins
- Morehouse
Ask authors/readers for more resources
Purpose of review In the past few years, tuberculosis (TB) has overtaken HIV as the infectious disease with the highest global mortality. Successful management of this syndemic will require improved diagnostic tests, shorter preventive therapies, and more effective treatments, particularly in light of drug-resistant TB. Recent findings Results from several major studies have been published or presented recently, including the development of a more sensitive rapid, molecular assay for TB; several new symptom-based screening tools; use of a 1-month regimen for TB prevention; the results of early vs. delayed TB preventive therapy for pregnant women; newer drugs and regimens for multidrug-resistant tuberculosis; and pharmacokinetic, safety, and efficacy studies of new HIV drugs in combination with TB treatment. We reviewed each of these topic areas and summarize relevant findings for the management of TB and HIV co-infection. Summary Moving forward, as new treatment regimes for HIV or TB are developed, consideration of the HIV-TB co-infected patient must figure prominently, both when determining the diagnostic tests employed and to assess properly the drug-drug and drug-disease interactions that influence dosing, safety, and response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available